Babiker Hamza A, Hastings Ian M, Swedberg Göte
Biochemistry Department, Faculty of Medicine, Sultan Qaboos University, Alkhod, Muscat, Oman.
Expert Rev Anti Infect Ther. 2009 Jun;7(5):581-93. doi: 10.1586/eri.09.29.
Malaria, a leading parasitic disease, inflicts an enormous toll on human lives and is caused by protozoal parasites belonging to the genus Plasmodium. Antimalarial drugs targeting essential biochemical processes in the parasite are the primary resources for management and control. However, the parasite has established mutations, substantially reducing the efficacy of these drugs. First-line therapy is faced the with the consistent evolution of drug-resistant genotypes carrying these mutations. However, drug-resistant genotypes are likely to be less fit than the wild-type, suggesting that they might disappear by reducing the volume of drug pressure. A substantial body of epidemiological evidence confirmed that the frequency of resistant genotypes wanes when active drug selection declines. Drug selection on the parasite genome that removes genetic variation in the vicinity of drug-resistant genes (hitch-hiking) is common among resistant parasites in the field. This can further disadvantage drug-resistant strains and limit their variability in the face of a mounting immune response. Attempts to provide unequivocal evidence for the fitness cost of drug resistance have monitored the outcomes of laboratory competition experiments of deliberate mixtures of sensitive and resistant strains, in the absence of drug pressure, using isogenic clones produced either by drug selection or gene manipulation. Some of these experiments provided inconclusive results, but they all suggested reduced fitness of drug-resistant clones in the absence of drug pressure. In addition, biochemical analyses provided clearer information demonstrating that the mutation of some antimalarial-targeted enzymes lowers their activity compared with the wild-type enzyme. Here, we review current evidences for the disadvantage of drug-resistance mutations, and discuss some strategies of drug deployment to maximize the cost of resistance and limit its spread.
疟疾是一种主要的寄生虫病,给人类生命造成了巨大损失,它由疟原虫属的原生动物寄生虫引起。针对寄生虫基本生化过程的抗疟药物是管理和控制疟疾的主要手段。然而,寄生虫已经发生了突变,大大降低了这些药物的疗效。一线治疗面临着携带这些突变的耐药基因型不断进化的问题。然而,耐药基因型可能比野生型适应性更差,这表明它们可能会因药物压力的降低而消失。大量的流行病学证据证实,当积极的药物选择减少时,耐药基因型的频率会下降。在野外的耐药寄生虫中,对寄生虫基因组进行药物选择以消除耐药基因附近的遗传变异(搭便车效应)是很常见的。这可能会进一步使耐药菌株处于劣势,并限制它们在面对不断增强的免疫反应时的变异性。为了提供耐药适应性代价的确凿证据,人们尝试在没有药物压力的情况下,使用通过药物选择或基因操作产生的同基因克隆,监测敏感菌株和耐药菌株故意混合后的实验室竞争实验结果。其中一些实验结果尚无定论,但它们都表明在没有药物压力的情况下,耐药克隆的适应性降低。此外,生化分析提供了更清晰的信息,表明与野生型酶相比,一些抗疟靶向酶的突变降低了它们的活性。在这里,我们回顾了目前关于耐药突变劣势的证据,并讨论了一些药物部署策略,以最大限度地增加耐药成本并限制其传播。